The therapeutic potential of TCs against pulmonary fibrosis has been recently reported in an in vitro study by Zhang et al., where the authors demonstrated that TCs were able to attenuate pulmonary fibrosis by preventing the epithelial-to-mesenchymal transition (EMT) in rat tracheal epithelial cells treated with TGFβ, mainly through the paracrine release of hepatocyte growth factor (HGF) [45]. The gene discussed is TGFB1; the disease is pulmonary fibrosis.